HER2‐positive patients treated with adjuvant anti‐HER2 therapy who had BC with positive HER2‐morphometric signature had significantly longer DMFS (p = 0.007, p = 0.004 in the discovery and test set, respectively) (Figure 9). This evidence concerns the gene ERBB2 and breast cancer.